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Abstract
Parkinson’s disease (PD) is marked pathologically by nigrostriatal dopaminergic terminal loss.
Histopathological and in vivo labeling studies demonstrate that this loss occurs most extensively
in the caudal putamen and caudate head. Previous structural studies have suggested reduced
striatal volume and atrophy of the caudate head in PD subjects. The spatial distribution of atrophy
in the putamen, however, has not been characterized. We aimed to delineate the specific locations
of atrophy in both of these striatal structures. T1- and T2-weighted brain MR (3T) images were
obtained from 40 PD and 40 control subjects having no dementia and similar age and gender
distributions. Shape analysis was performed using doubly segmented regions of interest.
Compared to controls, PD subjects had lower putamen (p=0.0003) and caudate (p=0.0003)
volumes. Surface contraction magnitudes were greatest on the caudal putamen (p≤0.005) and head
and dorsal body of the caudate (p≤0.005). This spatial distribution of striatal atrophy is consistent
with the known pattern of dopamine depletion in PD and may reflect global consequences of
known cellular remodeling phenomena.
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1 Introduction
Parkinson’s disease (PD) is the second most common age-related neurodegenerative
disorder and is characterized clinically by tremor at rest, bradykinesia, and rigidity (de Lau
and Breteler, 2006). Pathologically, PD is marked by loss of dopaminergic neurons in the
substantia nigra pars compacta of the midbrain (Jellinger, 2012; Braak et al., 2003).
Dopamine depletion of the striatum (putamen and caudate), resulting from the loss of
nigrostriatal terminals, reaches 60–80% before the onset of classic motor symptoms, most
severely affecting the caudal portion of the putamen and head of the caudate (Kish et al.,
1988; Rodriguez-Oroz et al., 2009; Otsuka et al., 1996; Lang and Obeso, 2004).
Previous studies have suggested that the striatum undergoes substantial cellular remodeling
throughout the course of PD progression. Dopamine-depleted animal and postmortem
studies of PD subjects, for example, have demonstrated reduced dendritic length and spine
density of the medium spiny neurons within the striatum (Ingham et al., 1993; Stephens et
al., 2005; McNeill et al., 1988). In humans, spine density is reduced particularly in the
caudal part of the putamen, where dopaminergic deficits are known to be most severe (Zaja-
Milatovic et al., 2005). Moreover, dopamine is known to play an important role in
maintaining striatal spine integrity (Villalba et al., 2009).
Several structural studies have suggested that the putamen and caudate undergo atrophy in
PD (for review, see Pitcher et al., 2012). One previous study by Apostolova et al. (2010)
demonstrated trend-level shape differences in the caudate between non-demented PD and
control subjects. The spatial distribution of atrophic areas of the putamen, however, remains
uncharacterized. Information regarding the pattern of striatal atrophy is important because it
may yield insight into the structural consequences of striatal cellular remodeling and also
may provide region-specific biomarkers that reflect PD disease progression. In this study,
we aimed to characterize these atrophic sites using a state-of-the-art protocol for
segmentation followed by shape analysis using spherical harmonic point distribution models
(SPHARM-PDM) (Styner et al., 2005). The present study included only non-demented
subjects in order to avoid potentially confounding influences of dementia-related
neuropathology. We hypothesized that striatal shape differences would be greatest in areas
that are known to be affected most severely by dopamine depletion and consequent striatal
spine pathology in PD, namely, the caudal portion of the putamen.
2 Methods
2.1 Subjects
Forty PD subjects (20 female, 20 male) and 40 healthy control subjects (20 female, 20 male)
having similar age distributions (61.3 ± 7.8 years for PD subjects, 59.4 ± 7.8 years for
control subjects) were recruited from a tertiary movement disorders clinic. PD diagnosis was
confirmed by a movement disorders specialist using published criteria (Hughes et al., 1992).
All subjects were confirmed for absence of other major and acute neurological and
psychological disorders, hypothyroidism, vitamin B12 and folate deficiency, and kidney and
liver disease. Unified Parkinson’s Disease Rating Scale section III motor scores (UPDRS-
III) were obtained for each subject, with PD subjects assessed after withholding PD
medications overnight (>12 hours) as a practically-defined off-drug state (Langston et al.,
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1992). Contralateral and ipsilateral sides were defined, respectively, as opposite to the body
sides having the greater and lesser UPDRS-III motor scores. Duration of illness (DOI) was
determined based on date of clinical diagnosis. Levodopa equivalent daily dose (LEDD) was
calculated using published criteria (Tomlinson et al., 2010). Written informed consent was
obtained for each subject, in accordance with the Declaration of Helsinki. The research
protocol was reviewed and approved by the Penn State Hershey Medical Center Institutional
Review Board.
2.2 Neuropsychological assessment
All subjects completed a basic neuropsychological battery to assess orientation, memory,
and symptoms of dementia. The Mini Mental State Exam (MMSE) is a brief (5-minute) 30-
point test that assesses orientation, memory and the ability to follow commands (Folstein et
al., 1975). The MMSE has been shown to have 98% sensitivity and 77% specificity in
detecting dementia among PD subjects using a cutoff score of 23 (Hobson and Meara,
1999). The Montreal Cognitive Assessment (MoCA) was developed to address the
limitations of the MMSE in detecting mild cognitive impairment (MCI) (Hoops et al., 2009)
and has been shown to have higher sensitivity for detecting PD-MCI than the MMSE
(Marras et al., 2013). The Dementia Rating Scale-2 (DRS2) examines a broader range of
cognitive functions (attention, initiation and perseveration, conceptualization, construction,
and memory) and has been demonstrated to be sensitive for detecting cognitive impairments
in PD (Brown et al., 1999). In this study, the cutoff for dementia was set at the 5th percentile
(i.e., 1.67 standard deviations below the mean), in line with recommended guidelines
(Monsch et al., 1995; Jurica et al., 2004). Subjects were included in this study only if they
had both an MMSE score > 24 and a DRS2 score > 5th percentile to ensure they were not
demented.
2.3 Image acquisition
All subjects were scanned using a 3.0 Tesla MR scanner (Trio, Siemens Magnetom,
Erlangen, Germany, with an 8-channel phased array head coil) and high-resolution T1- and
T2-weighted images were acquired. A magnetization-prepared rapid acquisition gradient
echo sequence was used to obtain T1-weighted images with TR=1540 ms, TE=2.34 ms,
field of view=256 mm, matrix=256×256, slice thickness=1 mm (with no gap), and slice
number=176. T2-weighted images were collected using a fast-spin-echo sequence with
TR=2500, TE=316, and the same resolution configuration as that for T1-weighted images.
2.4 Semi-automatic segmentation
Putamen and caudate structures were obtained using a semi-automatic region of interest
(ROI)-based approach. Probabilistic atlas-based automatic segmentation first was performed
using AutoSeg (Neuro Image Research and Analysis Laboratories, University of North
Carolina at Chapel Hill, NC, USA). This software features N4 bias field correction,
expectation-maximization tissue segmentation, skull striping, and probabilistic atlas-based
segmentation of subcortical structures (Lewis et al., 2009; Vachet et al., 2001; Van et al.,
1999; Van Leemput et al., 1999). The resulting ROIs then were manually corrected by an
investigator (NWS) blinded to subject diagnosis and symptoms using ITK-SNAP 2.2.0
(www.itksnap.org) (Yushkevich et al., 2006). In order to establish consistent boundaries of
the caudate and putamen, and to exclude the nucleus accumbens, manual corrections were
performed following the anatomical guidelines available in the UNC NeuroImage Analysis
Lab Manual (2007). In addition to the utilization of these guidelines for manual correction of
the striatal structures, the lateral ventricles also were segmented using the level-set region-
growing tool in ITK-SNAP, in order to maximize the accuracy of the caudate-ventricle
borders. To avoid potential left-right rater bias and increase the consistency of the final
ROIs, this semi-automated process was repeated after a delay of four weeks using a mirrored
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version of the original image set [in which left and right sides were inverted (Maltbie et al.,
2012)].
2.5 Volume extraction & average regions of interest
Volumes for each ROI were extracted from mirrored and original image sets and then were
averaged together, maintaining original left and right designations. Average ROIs from the
original and mirrored ROI sets also were generated for subsequent shape analysis using a
Gaussian averaging process. Mirrored ROIs first were reverted to their original orientations.
Subsequently, a Gaussian smoothing process (standard deviation = 0.3 mm) was applied to
the original and reverted mirrored ROIs. Intensity values of original and mirrored ROIs were
summed at each corresponding voxel and then scaled so that the maximum and minimum
intensities per combined ROI were 1 and 0, respectively. In order to yield average ROIs
having solid borders and fill, the combined ROIs then were binarized using an intensity
threshold of 0.8. This process of averaging the original and reverted mirrored ROIs was
performed in order to increase the accuracy of each shape and to correct for the known
phenomenon of asymmetric (right-left) rater bias (Maltbie et al., 2012).
2.6 Mesh generation, spherical parameterization, and alignment
Shape analysis was performed on the averaged ROIs using the SPHARM-PDM (Spherical
Harmonics Point Distribution Models) toolbox [Neuro Image Research and Analysis
Laboratories, University of North Carolina at Chapel Hill, NC, USA; (Styner et al., 2005;
Styner et al., 2003; Styner,M. et al., 2006b)]. The ROIs first were processed in order to fill
any internal holes and adapted to guarantee spherical topology. Surface meshes and
corresponding spherical parameterizations then were computed using area-preserving,
distortion minimizing spherical mapping. The SPHARM descriptions were generated from
surface meshes and their spherical parameterizations. The first order ellipsoids from the
spherical harmonic coefficients were used to establish initial correspondence between the
spherical parameterizations and each model was co-registered via generalized rigid
Procrustes alignment. The SPHARM descriptions then were sampled into surface meshes
with each of the 1,442 surface points by icosahedron subdivision. All models were scaled to
normalize for intracranial cavity volume differences. Models were inspected visually by an
independent investigator (ZN) for anatomical accuracy and proper alignment.
2.7 Statistical analyses
Demographic and clinical parameters were compared using Student’s t-tests. Group
comparisons of volumes (scaled as a percent of total intracranial volume) were performed by
analysis of covariance with adjustment for age and gender. Contralateral and ipsilateral
scaled volumes of PD subjects having unequal left and right UPDRS-III motor scores were
compared to the bilateral average of left and right volumes of all control subjects. Partial
correlation coefficients between clinical measurements and scaled striatal volumes were
computed after adjustment for age and gender effects. All volume analyses were performed
using SAS 9.3.
Group shape differences were analyzed using the multivariate analysis of covariance
(MANCOVA) tool that is part of the SPHARM-PDM toolkit (Styner,M. et al., 2006a;
Paniagua et al., 2009). Specifically, shape statistics were calculated by treating the three-
dimensional spatial coordinates as multivariate response variables at each surface point, and
by general linear modeling and permutation-based testing of the local Hotelling trace,
adjusted for age and gender. Vector field maps representing the displacement between the
PD and control models were generated by computing the distance and direction between
group mean surfaces at each pair of corresponding points (Paniagua et al., 2009). Pearson
correlation analyses of MoCA scores and shapes were performed for each surface point
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using general linear modeling of the distance from average surface (signed positively for
surface expansion and negatively for contraction) and MoCA residuals of regression on age
and gender. Topographical statistical significance maps for each surface coordinate were
generated after correction for multiple comparisons using false-discovery rate (FDR)
adjustment. Reported p-values for shape analyses were adjusted via the Benjamini-Hochberg
FDR p-value adjustment procedure using an expected proportion of incorrectly rejected null
hypotheses of 5% (Yekutieli and Benjamini, 1999). Points having an unadjusted p-value less
than or equal to the critical value were deemed real effects and were adjusted while others
were assigned p-values of 1.
3 Results
3.1 Study subjects & overlap of segmentations
Detailed subject characteristics and clinical parameters are summarized in Table 1. There
were no significant differences in age or cognitive assessment scores between PD and
control groups. In PD subjects, the mean time since diagnosis was 4.1 years with a range of
0.1–15.8 years. LEDD varied widely in PD subjects, ranging from 0–1,975 mg.
Analysis of overlap between the manually corrected original and reverted mirrored ROIs
was performed by computing the Dice coefficient of mean overlap for each striatal structure
(Tustison and Gee, 2009). The mean and standard deviations of overlap for left caudate,
right caudate, left putamen, and right putamen, respectively, were 0.9053±0.0234,
0.9062±0.0294, 0.9006±0.0279, and 0.9060±0.0225.
3.2 Volume comparisons between PD and control striatal structures
To account for possible effects of disease-related asymmetry, contralateral and ipsilateral
striatal structures were first compared in subjects having unequal left and right UPDRS-III
scores. This analysis revealed no asymmetry in volumes. Thus, striatal volumes were
averaged bilaterally for each subject and the mean volume was used in subsequent analyses.
PD subjects had significantly lower scaled striatal volumes (Table 2) than control subjects.
Average putamen volumes in PD subjects were 7.1% lower (p=0.0003) than controls and
caudate volumes were 7.0% lower (p=0.0003). Subgroup analysis of PD subjects with
shorter durations of illness (lowest 50% and lowest 25%) compared to controls showed
similar results (Table 2). Comparison of contralateral and ipsilateral volumes with bilaterally
averaged control volumes revealed significant differences for the putamen and caudate, as
did the unilateral comparisons of left and right volumes between PD and control subjects
(Supplemental Table 1).
3.3 Clinical correlations of striatal volumes in PD subjects
In PD subjects, scaled putamen volume correlated positively with MoCA scores after
adjustment for age and gender effects (Table 3). This relationship remained significant after
correction for multiple comparisons (p=0.0072). The correlation between scaled caudate
volume and MoCA scores revealed only a marginally significant relationship before
correction for multiple comparisons. Age and gender adjusted correlations between scaled
volume, MMSE, and DRS2 scores were not significant.
3.4 Shape comparisons of PD and control striatal structures
Contralateral and ipsilateral sides first were compared within the PD group for 36 subjects
having unequal left and right UPDRS-III scores. Similar to the volume analysis above, there
were no differences in shape between contralateral and ipsilateral structures. Thus, left and
right putamen and caudate models were pooled to compare PD and control shapes.
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Comparison of PD and control striatal shapes after adjustments for age and gender revealed
significant differences. For the putamen, the most statistically significant differences were
localized to the caudal and ventrolateral areas (p≤0.005; Figure 1). Inspection of the
displacement vector field map (Paniagua et al., 2009) revealed that the magnitude of surface
contraction was greatest in the caudal portion of the putamen (Figure 1, Supplemental
Figure 1). For the caudate, the most significant shape differences were present in the head
and dorsal body (p≤0.005; Figure 2). The greatest magnitudes of caudate surface contraction
were located at the most rostral extent of the caudate head (Figure 2, Supplemental Figure
2). Subgroup analysis comparing striatal shapes in all controls and PD subjects having
shorter durations of illness (lowest 50% and 25%) showed similar results.
Although no shape differences were found between contralateral and ipsilateral structures in
PD subjects, comparison of these shapes with pooled left and right control structures
revealed significant differences in the caudal regions of the contralateral and ipsilateral
putamen. The FDR-adjusted p-value maps revealed that, compared to the ipsilateral
putamen, a greater proportion of points on the caudal contralateral putamen were separated
significantly between groups (Supplemental Figure 3).
3.5 Clinical correlations of striatal shape in PD subjects
After the determination that MoCA was the only clinical measurement that was significantly
correlated with striatal volume, we focused our shape correlation analysis on this
measurement. Indeed, we found that MoCA scores, adjusted for age and gender, correlated
significantly with the signed distance from average surface on the dorsolateral and rostral
ventrolateral surfaces of the putamen (p≤0.005; Figure 3) and the body and dorsal surfaces
of the caudate (p≤0.005; Figure 4). We also explored potential striatal shape correlations
with other clinical measurements. No significant correlations between striatal shape and
other clinical measurements were observed after FDR-adjustment.
4 Discussion
The current data are consistent with previous reports of striatal atrophy in PD and indicate
that striatal shape differences between PD and control subjects are most robust in the caudal
part of the putamen and caudate head. These shape differences were present even in recently
diagnosed PD patients. To our knowledge, this is the first study demonstrating PD-related
shape differences in the putamen. Consistent with our hypothesis, these region-specific
shape differences are reflective of the known differential pattern of striatal dopamine
depletion and associated spine loss in PD (Kish et al., 1988; Rodriguez-Oroz et al., 2009;
Otsuka et al., 1996; Zaja-Milatovic et al., 2005). It is possible, therefore, that disruption of
dopaminergic innervation may play a role in the relatively early phenomenon of PD-related
striatal atrophy.
4.1 Technical innovations
Apostolova et al. (2010) studied shape differences in PD subjects across various stages of
cognitive decline and reported some differences in caudate shape between PD subjects (12
with normal cognition, 8 with mild cognitive impairment, and 15 with dementia) and 20
healthy controls. The current study differed substantially from that of Apostolova et al.
(2010) in terms of sample characteristics and methodologies. First, in order to evaluate
processes occurring relatively early in PD progression and exclude any confounds related to
dementia, we included only non-demented PD subjects. The average duration of disease
among the present PD subjects (4.1 years) also was much shorter [> 10 years in the report of
Apostolova et al. (2010)]. Second, Apostolova et al. (2010) used a machine learning
approach for segmentation, whereas we utilized a semi-automated ROI-based segmentation
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protocol that supplements the consistency of an atlas-based approach with the anatomic
validity of manually defined ROIs. Third, we controlled for the known phenomenon of left-
right rater segmentation bias by averaging original and left-right mirrored ROI sets (Maltbie
et al., 2012). Lastly, the present study utilized SPHARM-PDM (Styner et al., 2005) in order
to quantify shape differences, whereas the study by Apostolova et al. (2010) used radial
distance mapping (Thompson et al., 2004). Although radial distance has been used
previously to quantify putamen shape (Becker et al., 2011), the SPHARM-PDM shape
analysis technique provides direct modeling of surface information and local alignment of
shape.
4.2 Striatal shape characteristics and known cellular mechanisms
The current study is consistent with the findings of previous volume studies that suggest
striatal atrophy in PD (see review by Pitcher et al., 2012). Although the exact mechanisms of
volume and shape differences remain unknown, it is possible that striatal atrophy is linked,
at least in part, to cellular changes within the striatum that are triggered by inadequate or
fluctuating levels of dopamine (Lewis et al., 2006). It is well known that the most extensive
dopamine depletion in PD occurs in the caudal part of the putamen and head of the caudate
(Smith and Villalba, 2008; Geng et al., 2006; Krabbe et al., 2005; O'Neill et al., 2002;
Pitcher et al., 2012). The current shape analysis demonstrated that the striatal regions
bearing the greatest magnitude of shape contractions in PD correspond with these areas,
suggesting that dopaminergic dysfunction may contribute to the atrophic differences
demonstrated herein. Indeed, striatal spine loss has been demonstrated to be highly
dependent upon the degree of dopamine depletion in MPTP-treated monkeys, occurring
even in the absence of overt motor symptoms (Villalba et al., 2009). Furthermore, striatal
spine losses are known to be most severe in the caudal part of the putamen, bearing a
remarkable resemblance to the spatial pattern of shape differences described in the current
study (Zaja-Milatovic et al., 2005).
In addition to dopamine depletion, a number of other biochemical changes occur within the
PD striatum. Several lines of evidence suggest that glutamatergic synaptic and intraspine
calcium channel dysregulation may play key roles in PD-related striatal spine pathology
(Villalba and Smith, 2010; Burguière et al., 2013; Tian et al., 2010). Previous studies have
shown that reducing glutamate release may prevent and/or reverse dopamine depletion-
induced dendritic spine loss on medium spiny neurons (Neely et al., 2007; Garcia et al.,
2010). In addition, the administration of an L-type calcium channel blocker in an animal
model was shown to attenuate these spine losses (Soderstrom et al., 2010; Schuster et al.,
2009; Bezard, 2010).
Taken together, these early pathologic features, coupled with PD-related striatal shape
differences occurring in recently diagnosed individuals, offer the tantalizing hypothesis that
MRI-based striatal shape characteristics may serve as biomarkers for early PD-related
changes and for the evaluation of neuroprotective therapies. The sensitivity, specificity, and
longitudinal trajectories of shape measurements require further characterization in studies of
PD and Parkinsonism subjects.
4.3 Striatal shape characteristics and clinical associations
The MoCA is known to be a particularly sensitive instrument for detecting early cognitive
decline in PD (Dalrymple-Alford et al., 2010). The finding that striatal volume and shape
correlate significantly with MoCA scores in PD subjects is consistent with the notion that
the striatum has a complex role in normal cognition as part of several large-scale neural
networks. The rostral portions of the putamen and caudate are known to receive projections
from the dorsolateral, orbital, and medial prefrontal cortices (Haber, 2003). Similarly, limbic
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projections from the hippocampus and amygdala project to the ventral regions of the
striatum. These striatal limbic, associative, and motor circuits are highly integrated and
allow for a hierarchical flow of information through the striatal system (Haber et al., 2000).
In line with the cognitive correlations demonstrated herein, which are primarily localized to
the rostral regions of the putamen and the body and most dorsal extent of the caudate,
frontostriatal dysfunction is well documented in PD and may be responsible for some
neuropsychological deficits that occur throughout disease progression (Lewis et al., 2003;
Brown et al., 1997).
4.4 Limitations and conclusions
The cross-sectional nature of the study design and individual variations in the rate of disease
progression, coupled with the relatively broad ranges of disease duration and clinical
staging, made impossible the assessment of time-related changes. Longitudinal follow-up of
this cohort will be necessary to confirm volume and shape alterations as dynamic
components of PD progression. In addition, the anatomical precision in segmenting the
caudate head was inherently limited by its rostroventral junction with the nucleus
accumbens. Although group differences were demonstrated in the most rostral extent of the
caudate head, this area may have some degree of overlap with the junction of the nucleus
accumbens and thus changes may not be limited exclusively to the caudate head. Lastly, in
order for shape analysis to become practical in future clinical trials and medical practice,
reliable fully automatic processes are needed. Nevertheless, this study demonstrated region-
specific shape differences measured via MRI within the putamen and caudate of PD patients
that are consistent with the known differential pattern of PD-related dopamine depletion in
the striatum. We propose that shape characteristics may be useful for reflecting structural
changes that occur relatively early in PD.
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Putamen shape differences between 40 PD and 40 control subjects. Displacement vectors
indicate the direction and magnitude (M) of distance from the average control surface to the
average PD surface. FDR-adjusted p-values are for comparisons between PD and control
structures, adjusted for age and gender. The greatest magnitudes of surface contraction were
located on the caudal putamen. Structures were pooled bilaterally and scaled to account for
variations in intracranial volume.
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Caudate shape differences between 40 PD and 40 control subjects. Displacement vectors
indicate the direction and magnitude (M) of distance from the average control surface to the
average PD surface. FDR-adjusted p-values are for comparisons between PD and control
structures, adjusted for age and gender. The greatest magnitudes of surface contraction were
located on the rostral caudate head. Structures were pooled bilaterally and scaled to account
for variations in intracranial volume.
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Correlation of putamen shape and MoCA scores in 40 PD subjects. Worsening MoCA
scores are related to contraction of the dorsal and rostroventral surfaces. Pearson’s R and
FDR-adjusted p-value maps represent correlations between signed distance from average
surface at each surface point and MoCA score residuals after regression for age and gender.
Structures were pooled bilaterally and scaled to account for variations in intracranial
volume.
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Correlation of caudate shape and MoCA scores in 40 PD subjects. Worsening MoCA scores
are related to contractions on the dorsal surface and body of the caudate. Pearson’s R and
FDR-adjusted p-value maps represent correlations between signed distance from average
surface at each surface point and MoCA score residuals after regression for age and gender.
Structures were pooled bilaterally and scaled to account for variations in intracranial
volume.
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Table 1
Demographic and clinical information of PD and control subjects
Control (SD) PD (SD) P-Value
  Total N [F/M] 40 [20/20] 40 [20/20] NA
  Age 59.4 (7.8) 61.3 (7.8) 0.2670a
  Years Since Diagnosis NA 4.1 (4.2) NA
Motor Measurements
  Hoehn-Yahr Stage 0 (0) 1.8 (0.6) < 0.0001b
  UPDRS-III 1.1 (1.26) 22.6 (14.7) < 0.0001b
  LEDD (mg) NA 465.3 (376.8) NA
Cognitive Measurements
  DRS2 141.2 (2.3) 140.2 (3.6) 0.1447a
  MMSE 29.5 (0.8) 29.2 (1.2) 0.1840b
  MoCA 25.8 (2.4) 25.6 (2.9) 0.7360b
All values are presented as group means and standard deviations (SD), except for the number and gender of subjects. Motor and cognitive
measurements in PD subjects were obtained in the off-medication state (see Methods).
a
P-values calculated using two-sample t-tests with pooled variance.
b
P-values calculated using two-sample t-tests with non-pooled variance.
Abbreviations: DRS2 = Dementia Rating Scale-2; LEDD = levodopa equivalent daily dose; MMSE = Mini Mental State Examination; MoCA =
Montreal Cognitive Assessment; UPDRS-III = Unified Parkinson’s Disease Rating Scale section III.
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Table 2
Striatal volumes (percent of intracranial volume) in PD and control subjects
PD Control PD/Control (%) P-Value
Analysis of all subjectsa
    N 40 40
    Putamen 0.306 (0.00434) 0.330 (0.00434) 92.9 0.0003
    Caudate 0.228 (0.00316) 0.245 (0.00316) 93.0 0.0003
Subgroup analysisb
  PD subjects 0.1 – 2.3 years since diagnosis
    N 20 40
    Putamen 0.306 (0.00653) 0.331 (0.00493) 92.5 0.0024
    Caudate 0.232 (0.00551) 0.247 (0.00420) 94.0 0.0036
  PD subjects 0.1 – 1.1 years since diagnosis
    N 10 40
    Putamen 0.302 (0.00974) 0.331 (0.00493) 91.3 0.0061
    Caudate 0.234 (0.00698) 0.247 (0.00420) 94.7 0.0248
a
Adjusted mean scaled volumes and standard errors.
b
Unadjusted mean scaled volumes and standard errors.
All p-values are adjusted for age and gender.
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Table 3




























Spearman’s partial correlation coefficients after adjustment for age and gender.
b
Pearson’s partial correlation coefficients after adjustment for age and gender.
*
Significant after Bonferroni correction for multiple comparisons (p=0.0072).
Abbreviations: DRS2 = Dementia Rating Scale-2; LEDD = levodopa equivalent daily dose; MMSE = Mini Mental State Examination; MoCA =
Montreal Cognitive Assessment; UPDRS-III = Unified Parkinson’s Disease Rating Scale section III.
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